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A clinical prediction model can be applied to several challenging clinical scenarios: screening high-risk individuals for asymp-
tomatic disease, predicting future events such as disease or death, and assisting medical decision-making and health education. 
Despite the impact of clinical prediction models on practice, prediction modeling is a complex process requiring careful statisti-
cal analyses and sound clinical judgement. Although there is no definite consensus on the best methodology for model develop-
ment and validation, a few recommendations and checklists have been proposed. In this review, we summarize five steps for de-
veloping and validating a clinical prediction model: preparation for establishing clinical prediction models; dataset selection; 
handling variables; model generation; and model evaluation and validation. We also review several studies that detail methods 
for developing clinical prediction models with comparable examples from real practice. After model development and vigorous 
validation in relevant settings, possibly with evaluation of utility/usability and fine-tuning, good models can be ready for the use 
in practice. We anticipate that this framework will revitalize the use of predictive or prognostic research in endocrinology, leading 
to active applications in real clinical practice.
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INTRODUCTION
Hippocrates emphasized prognosis as a principal component of 
medicine [1]. Nevertheless, current medical investigation 
mostly focuses on etiological and therapeutic research, rather 
than prognostic methods such as the development of clinical 
prediction models. Numerous studies have investigated wheth-
er a single variable (e.g., biomarkers or novel clinicobiochemi-
cal parameters) can predict or is associated with certain out-
comes, whereas establishing clinical prediction models by in-
corporating multiple variables is rather complicated, as it re-
quires a multi-step and multivariable/multifactorial approach to 
design and analysis [1]. 
 Clinical prediction models can inform patients and their 
physicians or other healthcare providers of the patient’s proba-
bility of having or developing a certain disease and help them 
with associated decision-making (e.g., facilitating patient-doc-
tor communication based on more objective information). Ap-
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plying a model to a real world problem can help with detection 
or screening in undiagnosed high-risk subjects, which improves 
the ability to prevent developing diseases with early interven-
tions. Furthermore, in some instances, certain models can pre-
dict the possibility of having future disease or provide a prog-
nosis for disease (e.g., complication or mortality). This review 
will concisely describe how to establish clinical prediction 
models, including the principles and processes for conducting 
multivariable prognostic studies and developing and validating 
clinical prediction models. 
CONCEPT OF CLINICAL PREDICTION 
MODELS
In the era of personalized medicine, prediction of prevalent or 
incident diseases (diagnosis) or outcomes for future disease 
course (prognosis) became more important for patient manage-
ment by health-care personnel. Clinical prediction models are 
used to investigate the relationship between future or unknown 
outcomes (endpoints) and baseline health states (starting point) 
among people with specific conditions [2]. They generally 
combine multiple parameters to provide insight into the relative 
impacts of individual predictors in the model. Evidence-based 
medicine requires the strongest scientific evidence, including 
findings from randomized controlled trials, meta-analyses, and 
systematic reviews [3]. Although clinical prediction models are 
partly based on evidence-based medicine, the user must also 
adopt practicality and an artistic approach to establish clinically 
relevant and meaningful models for targeted users. 
 Models should predict specific events accurately and be rela-
tively simple and easy to use. If a prediction model provides 
inaccurate estimates of future-event occurrences, it will mislead 
healthcare professionals to provide insufficient management of 
patients or resources. On the other hand, if a model has high 
predictability power but is difficult to apply (e.g., with compli-
cated calculation or unfamiliar question/item or unit), time con-
suming, costly [4] or less relevant (e.g., European model for 
Koreans, event too far away), it will not be commonly used. 
For example, a diabetes prediction model developed by Lim et 
al. [5] has a relatively high area under the receiver operating 
curve (AUC, 0.77), while blood tests that measure hemoglobin 
A1c, high density lipoprotein cholesterol, and triglyceride are 
included in the risk score, which would generally require clini-
cian’s involvement so could be a major barrier for use in com-
munity settings. When prediction models consist of complicat-
ed mathematical equations [6,7], a web-based application can 
enhance implementation (e.g., calculating 10-year and lifetime 
risk for atherosclerotic cardiovascular disease [CVD] is avail-
able at http://tools.acc.org/ASCVD-Risk-Estimator/). There-
fore, achieving a balance between predictability and simplicity 
is a key to a good clinical prediction model. 
STEPS TO DEVELOPING CLINICAL 
PREDICTION MODELS
There are several reports [1,8-13] and a textbook [14] that de-
tail methods to develop clinical prediction models. Although 
there is currently no consensus on the ideal construction meth-
od for prediction models, the Prognosis Research Strategy 
(PROGRESS) group has proposed a number of methods to im-
prove the quality and impact of model development [2,15]. Re-
cently, investigators on the Transparent Reporting of a multi-
variable prediction model for Individual Prognosis Or Diagno-
sis (TRIPOD) study have established a checklist of recommen-
dations for reporting on prediction or prognostic models [16]. 
This review will summarize the analytic process for developing 
clinical prediction models into five stages. 
Stage 1: preparation for establishing clinical prediction 
models
The aim of prediction modeling is to develop an accurate and 
useful clinical prediction model with multiple variables using 
comprehensive datasets. First, we have to articulate several im-
portant research questions that affect database selection and the 
approach of model generation. (1) What is the target outcome 
(event or disease) to predict (e.g., diabetes, CVD, or fracture)? 
(2) Who is the target patient of the model (e.g., general popula-
tion, elderly population ≥65 years or patients with type 2 dia-
betes)? (3) Who is the target user of the prediction model (e.g., 
layperson, doctor or health-related organization)? Depending 
on the answers to the above questions, researchers can choose 
the proper datasets for the model. The category of target users 
will determine the selection and handling process of multiple 
variables, which will affect the structure of the clinical predic-
tion model. For example, if researchers want to make a predic-
tion model for laypersons, a simple model with not many user-
friendly questions in only a few categories (e.g., yes vs. no) 
could be ideal. 
Stage 2: dataset selection
The dataset is one of the most important components of the 
clinical prediction model—often not under investigators’ con-
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trol—and ultimately determines its quality and credibility; 
however, there are no general rules for assessing the quality of 
data [9]. Yet, there is no such thing as perfect data and prefect 
model. It would be reasonable to search for best-suited dataset. 
Oftentimes, secondary or administrative data sources must be 
utilized because a primary dataset with the study endpoint and 
all of key predictors is not available. Researchers should use 
different types of datasets, depending on the purpose of the 
prediction model. For example, a model for screening high-risk 
individuals with undiagnosed condition/disease can be devel-
oped using cross-sectional cohort data. However, such models 
may have relatively low power for predicting future incidence 
of disease when different risk factors come into play. Accord-
ingly, longitudinal or prospective cohort datasets should be 
used for prediction models for future events (Table 1). Models 
for prevalent events are useful for predicting asymptomatic 
diseases, such as diabetes or chronic kidney disease, by screen-
ing undiagnosed cases, whereas models for incident events are 
useful for predicting the incidence of relatively severe diseases, 
such as CVD, stroke, and cancer.
 A universal clinical prediction model for disease does not 
exist; thus, separate specific models that can individually as-
sess the role of ethnicity, nationality, sex, or age on disease risk 
are warranted. For example, the Framingham coronary heart 
disease (CHD) risk score is generated by one of the most com-
monly used clinical prediction models; however, it tends to 
overestimate CHD risk by approximately 5-fold in Asian popu-
lations [17,18]. This indicates that models derived from one 
ethnicity sample may not be directly applied to populations of 
other ethnicities. Other specific characteristics of study popula-
tions beside ethnicity (e.g., obesity- or culture-related vari-
ables) could be important. 
 There is no absolute consensus on the minimal requirement 
for dataset sample size. Generally, large representative, contem-
porary datasets that closely reflect the characteristics of their 
target population are ideal for modeling and can enhance the 
relevance, reproducibility, and generalizability of the model. 
Moreover, two types of datasets are generally needed: a devel-
opment dataset and a validation dataset. A clinical prediction 
model is first derived from analyses of the development dataset 
and its predictive performance should be assessed in different 
populations based on the validation dataset. It is highly recom-
mended to use validation datasets from external study popula-
tions or cohorts, whenever available [19,20]; however, if it is 
not possible to find appropriate external datasets, an internal 
validation dataset can be formed by randomly splitting the orig-
inal cohort into two datasets (if sample size is large) or statisti-
cal techniques such as jackknife or bootstrap resampling (if not) 
[21]. The splitting ratio can vary depending on the researchers’ 
particular goals, but generally, more subjects should be allocat-
ed to the development dataset than to the validation dataset. 
Stage 3: handling variables
Since cohort datasets contain more variables than can reason-
ably be used in a prediction model, evaluation and selection of 
the most predictive and sensible predictors should be done. 
Generally, inclusion of more than 10 variables/questions may 
decrease the efficiency, feasibility and convenience of predic-
tion models, but expert’s judgment that could be somewhat 
subjective is required to assess the need for each situation. Pre-
dictors that were previously found to be significant should nor-
mally be considered as candidate variables (e.g., family history 
of diabetes in diabetes risk score). It should be noted that not 
all significant predictors need to be included in the final model 
(e.g., P<0.05); predictor selection must be always guided by 
clinical relevance/judgement to prevent nonsensical or less rel-
evant or user-unfriendly variables (e.g., socioeconomic status-
related) or possible false-positive associations. Additionally, 
Table 1. Characteristics of Different Clinical Prediction Models according to Their Purpose   
Characteristic Prevalent/concurrent events Incident/future events
Data type Cross-sectional data Longitudinal/prospective cohort data
Application Useful for asymptomatic diseases for screening 
 undiagnosed cases (e.g., diabetes, CKD) 
Useful for predicting the incidence of diseases 
 (e.g., CVD, stroke, cancer)
Aim of the model Detection Prevention
Simplicity in model and use More important Less important
Example Korean Diabetes Score [34] ACC/AHA ASCVD risk equation [7]
CKD, chronic kidney disease; CVD, cardiovascular disease; ACC/AHA, American College of Cardiology/American Heart Association; ASCVD, 
atherosclerotic cardiovascular disease.  
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variables which are highly correlated with others may be ex-
cluded because they contribute little unique information [22]. 
On the other hand, variables not statistically significant or with 
small effect size may still contribute to the model [23]. De-
pending on researcher discretion, different models that analyze 
different variables may be developed for targeting distinct us-
ers. For example, a simple clinical prediction model that does 
not require laboratory variables and a comprehensive model 
that does could both be designed for laypersons and health care 
providers, respectively [19]. 
 With regard to variable coding, categorical and continuous 
variables should be managed differently [8]. For ordered cate-
gorical variables, infrequent categories can be merged and sim-
ilar variables may be combined/grouped. For example, past and 
current smoker categories can be merged if numbers of sub-
jects who report being a past or current smoker are relatively 
small and variable unification does not alter the statistical sig-
nificance of the model materially. Although continuous param-
eters are usually included in a regression model, assuming lin-
earity, researchers should consider the possibility of non-linear 
associations such as J- or U-shaped distributions [24]. Further-
more, the relative effect of a continuous variable is determined 
by the measurement scale used in the model [8]. For example, 
the impact of fasting glucose levels on the risk of CVD may be 
interpreted as having a stronger influence when scaled per 10 
mg/dL than per 1 mg/dL. 
 Researchers often emphasize the importance of not dichoto-
mizing continuous variables in the initial stage of model devel-
opment because valuable predictive information can be lost 
during categorization [24]. However, prediction models—is 
not the same thing as regression models—with continuous pa-
rameters may be complex and hard to use or be understood by 
laypersons, because they have to calculate their risk scores by 
themselves. A web or computer-based platform is usually re-
quired for the implementation of these models. Otherwise, in a 
later phase, researchers may transform the model into a user-
friendly format by categorizing some predictors, if the predic-
tive capacity of the model is retained [8,19,25].
 Finally, missing data is a chronic problem in most data anal-
yses. Missing data can occur various reasons, including uncol-
lected (e.g., by design), not available or not applicable, refusal 
by respondent, dropout, or “don’t know.” To handle this issue, 
researchers may consider imputation technique, dichotomizing 
the answer into yes versus others, or allow “unknown” as a 
separate category as in http://www.cancer.gov/bcrisktool/.
Stage 4: model generation
Although there are no consensus guidelines for choosing vari-
ables and determining structures to develop the final prediction 
model, various strategies with statistical tools are available 
[8,9]. Regression analyses, including linear, logistic, and Cox 
models are widely used depending on the model and its intend-
ed purpose. First, the full model approach is to include all the 
candidate variables in the model; the benefit of this approach is 
to avoid overfitting and selection bias [9]. However, it can be 
impractical to pre-specify all predictors and previously signifi-
cant predictors may not be in a new population/sample. Sec-
ond, a backward elimination approach or stepwise selection 
method can be applied to remove a number of insignificant 
candidate variables. To check for overfitting of the model, 
Akaike information criterion (AIC) [26], an index of model fit-
ting that charges a penalty against larger models, may be useful 
[19]. Lower AIC values indicate a better model fit. Some inter-
pret that AIC addresses explanation and Bayesian information 
criterion (BIC) addresses prediction, where BIC may be con-
sidered a Bayesian counterpart [27].
 If researchers prefer algorithm modeling culture instead of 
data modeling culture, e.g., formula-based regression [28], a 
classification and regression tree analysis or recursive parti-
tioning could be considered [28-30].
 With regard to determining scores for each predictor in the 
generation of simplified models, researchers using expert judg-
ment may create a weighted scoring system by converting β 
coefficients [19] or odds ratios [20] from the final model to in-
teger values, while preserving monotonicity and simplicity. For 
example, from the logistic regression model built by Lee et al. 
[19], β coefficients <0.6, 0.7 to 1.3, 1.4 to 2.0, and >2.1 were 
assigned scores of 1, 2, 3, and 4, respectively.
Stage 5: model evaluation and validation (internal/
external)
After model generation, researchers should evaluate the predic-
tive power of their proposed model using an independent datas-
et, where truly external dataset is preferred whenever available. 
There are several standard performance measures that capture 
different aspects: two key components are calibration and dis-
crimination [8,9,31]. Calibration can be assessed by plotting the 
observed proportions of events against the predicted probabili-
ties for groups defined by ranges of individual predicted risk 
[9,10]. For example, a common method is to categorize 10 risk 
groups of equal size (deciles) and then conduct the calibration 
process [32]. The most ideal calibration plot would show a 45° 
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line, which indicates that the observed proportions of events 
and predicted probabilities completely overlap over the entire 
range of probabilities [9]. However, this is not guaranteed when 
external validation is conducted with a different sample. Dis-
crimination is defined as the ability to distinguish events versus 
non-events (e.g., dead vs. alive) [8]. The most common dis-
crimination measure is the AUC or, equivalently, concordance 
(c)-statistic. The AUC is equal to the probability that, given two 
individuals randomly selected—one who will develop an event 
and another who will not—the model will assign a higher prob-
ability of an event to the former [10]. A c-statistic value of 0.5 
indicates a random chance (i.e., flip of a coin). The usual c-sta-
tistic range for a prediction model is 0.6 to 0.85; this range can 
be affected by target-event characteristics (disease) or the study 
population. A model with a c-statistic ranging from 0.70 to 0.80 
has an adequate power of discrimination; a range of 0.80 to 0.90 
is considered excellent. Table 2 shows several common statisti-
cal measures for model evaluation.
 As usual, selection, application and interpretation of any sta-
tistical method and results need great care as virtually all meth-
ods entail assumptions and limited capacity. Let us review 
some here. Predictive values depend on the disease prevalence 
so direct comparison for different diseases may not be valid. 
When sample size is very large, P value can be impressively 
small even for a practically meaningless difference. Net reclas-
sification index and integrated discrimination improvement are 
known to lead to non-proper scoring and vulnerable to miscali-
brated or overfit problems [33]. AUC and R2 are often hard to 
increase by a new predictor, even with large odds ratio. Despite 
similar names, AIC and BIC address slightly different issues and 
information in BIC can be decreased with sample size increases. 
The Hosmer-Lemeshow test is highly sensitive when sample 
size is large, which is not an ideal property as a goodness-fit sta-
tistic. Calibration plot can easily provide a high correlation coef-
ficient (>0.9), simply because they are computed for predicted 
versus observed values on grouped data (without random vari-
ability). Finally, AUC also needs caution: a high value (e.g., 
>0.9) may mean excellent discrimination but it can also reflect 
the situation where prediction is not so relevant: (1) the task is 
closer to diagnostic or early onset rather than prediction; (2) cas-
es vs. non-cases are fundamentally different with minimal over-
lap; or (3) predictors and endpoints are virtually the same things 
(e.g., current blood pressure vs. future blood pressure). 
 Despite the long list provided above, we do not think this is 
a discouraging news to researchers. We may tell us no method 
is perfect and “one size does not fit all” is also true to statistical 
methods; thus blinded or automated application can be danger-
ous. 
 It is crucial to separate internal and external validation and 
to conduct the previously mentioned analyses on both datasets 
to finalize the research findings (see the following for example 
reports [19,20,34]). Internal validation can be done using a ran-
dom subsample or different years from the development dataset 
or by conducting bootstrap resampling [22]. This approach can 
particularly assess the stability of selected predictors, as well as 
prediction quality. Subsequently, external validation should be 
performed on an independent dataset from that which was pre-
viously used to develop the model. For example, datasets can 
be obtained from populations from other hospitals or centers 
(see geographic validation [19]) or a more recently collected 
cohort population (temporal validation [34]). This process is 
often considered to be a more powerful test for prediction mod-
els than internal validation because it evaluates transportability, 
generalizability and true replication, rather than reproducibility 
[8]. Poor model performance may occur after use of an external 
dataset due to differences in healthcare systems, measurement 
methods/definitions of predictors and/or endpoint, subject 
characteristics or context (e.g., high vs. low risk).
CONCLUSIONS
For patient-centered perspectives, clinical prediction models 
are useful for several purposes: to screen high-risk individuals 
Table 2. Statistical Measures for Model Evaluation 
Sensitivity and specificity
Discrimination (ROC/AUC)
Predictive values: positive, negative
Likelihood ratio: positive, negative 
Accuracy: Youden index, Brier score
Number needed to treat or screen
Calibration: Calibration plot, Hosmer-Lemeshow test
Model determination: R2
Statistical significance: P value (e.g., likelihood ratio test) 
Magnitude of association, e.g., β coefficient, odds ratio
Model quality: AIC/BIC 
Net reclassification index and integrated discrimination improvement 
Net benefit
Cost-effectiveness
ROC, receiver operating characteristic; AUC, area under the curve; 
AIC, Akaike information criterion; BIC, Bayesian information criterion. 
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for asymptomatic disease, to predict future events of disease or 
death, and to assist medical decision-making. Herein, we sum-
marized five steps for developing a clinical prediction model. 
Prediction models are continuously designed but few have had 
their predictive performance validated with an external popula-
tion. Because model development is complex, consultation 
with statistical experts can improve the validity and quality of 
rigorous prediction model research. After developing the mod-
el, vigorous validation with multiple external datasets and ef-
fective dissemination to interested parties should occur before 
using the model in practice [35]. Web or smartphone-based ap-
plications can be good routes for advertisement and delivery of 
clinical prediction models to the public. For example, Korean 
risk models for diabetes, fatty liver, CVD, and osteoporosis are 
readily available at http://cmerc.yuhs.ac/mobileweb/. Simple 
model may be translated into a one page checklist for patient’s 
self-assessment (e.g., equipped in waiting room in clinic). We 
anticipate that the framework that we provide/summarize, 
along with additional assistance from related references or text-
books, will help predictive or prognostic research in endocri-
nology; this will lead to active application of these practices in 
real world settings. In light of the personalized- and precision-
medicine era, further research is needed to attain individual-
level predictions, where genetic or novel biomarkers can play 
bigger roles, as well as simple generalized predictions which 
can further help patient-centered care.
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